Recently Added
News
Delivering Big Ideas from ASH 2025
At Fox Chase Cancer Center and Temple University Hospital, it’s “in the blood” of our residents and Fellows to develop innovative scientific ideas that significantly affect the way blood diseases are diagnosed and treated. Here is the latest from ASH 2025:
News
Fox Chase Cancer Center and Temple Health physicians and scientists participated in the presentation and discussion of eight research projects at the American Society of Hematology (ASH) 2024 Annual Meeting, held this past December in San Diego.
News
The study is a phase one, single-site, dose-escalation study for patients with myeloproliferative neoplasms unresponsive to any JAK2 inhibitor. It combines two oral medications, Pacritinib and Talazoparib, and is for transplant-ineligible patients.
News
High Expectations for Adoptive Cell Therapy for Treatment of Solid Tumors
A partnership between the Fox Chase solid tumor oncologists and their colleagues in bone marrow transplantation tests the potential of adoptive cell therapies for the treatment of solid tumors.
News
CAR T-Cell Therapy Now Available at Fox Chase for Relapsed and Refractory Mantle Cell Lymphoma
Patients with mantle cell lymphoma treated at Fox Chase Cancer Center will now have access to treatment with brexucabtagene autoleucel (also known as TecartusTM), the first cell-based gene therapy approved by the Food and Drug Administration (FDA).
